ProCE Banner Activity

Addressing BTK Inhibitor Toxicities in B-Cell Malignancies

Slideset Download
Download these slides for expert strategies on monitoring for and managing toxicities associated with BTK inhibitor therapy in patients with B-cell malignancies.

Released: September 29, 2021

Expiration: September 28, 2022

Share

Faculty

Christopher R. Flowers

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Faculty Disclosure

Primary Author

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS, has disclosed that he has received consulting fees from AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Genmab, Gilead Sciences, Janssen, Karyopharm, Pharmacyclics, Seattle Genetics, and Spectrum and funds for research support from 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research, Celgene, Cellectis, Eastern Cooperative Oncology Group, EMD, Genentech/Roche, Gilead Sciences, Guardant, Iovance, Janssen, Kite, Morphosys, National Cancer Institute, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda Pharmaceuticals, TG Therapeutics, V Foundation, Xencor, and Ziopharm.